Please assess the completion status of the following clinical trial:

Trial Title: Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with ongoing post-bariatric hypoglycemia with prior episodes of neuroglycopenia, unresponsive to dietary intervention (low glycemic index, controlled carbohydrate portions) and trial of acarbose therapy at the maximally tolerated dose.~* willingness to provide informed consent and follow all study procedures, including attending all scheduled visits.~Exclusion Criteria:~* documented hypoglycemia occurring in the fasting state (\> 12 hours fast);~* chronic kidney disease stage 4 or 5;~* hepatic disease, including serum alanine aminotransferase or aspartate aminotransferase greater than or equal to 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as serum albumin \< 3.0 g/dL; or serum bilirubin \> 2.0;~* congestive heart failure, New York Heart Association class II, III or IV;~* history of myocardial infarction, unstable angina or revascularization within the past 6 months;~* history of a cerebrovascular accident;~* seizure disorder (other than with suspect or documented hypoglycemia);~* active treatment with any diabetes medications except for acarbose;~* active malignancy, except basal cell or squamous cell skin cancers;~* personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease);~* known insulinoma;~* major surgical operation within 30 days prior to screening;~* hematocrit ≤ 33%;~* bleeding disorder, treatment with warfarin, or platelet count \<50,000;~* blood donation (1 pint of whole blood) within the past 2 months;~* active alcohol abuse or substance abuse;~* current administration of oral or parenteral corticosteroids;~* pregnancy and/ or Lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.~* use of an investigational drug within 30 days prior to screening.~* there will be no involvement of special vulnerable populations such as pregnant women, prisoners, institutionalized or incarcerated individuals, or others who may be considered vulnerable populations.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G-Pump™ (glucagon infusion) (Type: EXPERIMENTAL): 0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump

Based on this trial design, predict the completion outcome and termination type (if applicable).